part 2 of 2. glp-1 agonists have been shown to reduce several inflammatory markers including...
TRANSCRIPT
![Page 1: Part 2 of 2. GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular](https://reader035.vdocuments.us/reader035/viewer/2022062803/56649f265503460f94c3d8ad/html5/thumbnails/1.jpg)
Part 2 of 2
![Page 2: Part 2 of 2. GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular](https://reader035.vdocuments.us/reader035/viewer/2022062803/56649f265503460f94c3d8ad/html5/thumbnails/2.jpg)
![Page 3: Part 2 of 2. GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular](https://reader035.vdocuments.us/reader035/viewer/2022062803/56649f265503460f94c3d8ad/html5/thumbnails/3.jpg)
![Page 4: Part 2 of 2. GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular](https://reader035.vdocuments.us/reader035/viewer/2022062803/56649f265503460f94c3d8ad/html5/thumbnails/4.jpg)
![Page 5: Part 2 of 2. GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular](https://reader035.vdocuments.us/reader035/viewer/2022062803/56649f265503460f94c3d8ad/html5/thumbnails/5.jpg)
GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activa tor inhibitor-1 (PAI-1), vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) E-selectin was not significantly reduced
C-reactive protein has also been associated with increased cardiovascular disease Patients treated with exenatide showed marked
decrease in c-reactive protein levels after an 82-week study (from 3.21mg/dL to 1.35 mg/dL)
Kendall DM, Bhole D, Guan X, et al.: Exenatide treatment for 82 weeks reduced C-reactive protein, HbAlc, and body weight in patients with type 2 diabetes mellitus. Presented at 42nd Congress of EASD.Copenhagen, Denmark; September 14-17, 2006.
![Page 6: Part 2 of 2. GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular](https://reader035.vdocuments.us/reader035/viewer/2022062803/56649f265503460f94c3d8ad/html5/thumbnails/6.jpg)
![Page 7: Part 2 of 2. GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular](https://reader035.vdocuments.us/reader035/viewer/2022062803/56649f265503460f94c3d8ad/html5/thumbnails/7.jpg)
![Page 8: Part 2 of 2. GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular](https://reader035.vdocuments.us/reader035/viewer/2022062803/56649f265503460f94c3d8ad/html5/thumbnails/8.jpg)
50,330 patients taking exenatide with insulin and another antidiabetic treatment were 57% less likely to develop heart failure compared to those that took insulin, antidiabetic treatment, but no exenatide (OR 0.43; 95% CI 0.35-0.53)
53,446 patients who received exenatide and other noninsulin therapies were 31% less likely to develop heart failure compared to those that took a noninsulin therapy and no exenatide (OR 0.69; 95% CI 0.44-1.07)
After combining data, patients who took exenatide were 54% less likely to develop heart failure than those that were not (OR 0.46; 95% CI 0.38-0.56)
Best JH, Maggs D, Little W, et al. The risk of heart failure among patients receiving exenatide twice daily versus other glucose-lowering medications for diabetes: a matched retrospective analysis of the GE Healthcare EMR data. Diabetologia 2011; 54(Suppl. 1): S1–S542.
![Page 9: Part 2 of 2. GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular](https://reader035.vdocuments.us/reader035/viewer/2022062803/56649f265503460f94c3d8ad/html5/thumbnails/9.jpg)
↑ Cardiac output, ↓ LV end diastolic pressure, and ↑ myocardial glucose uptake in animal (rodent and dog) models of CHF and myocardial injury
↓ Infarct size in ischemic animal models
↑ LVEF and ↑ wall motion in humans with MI and EF <40%
GLP-1 (9-36)amide ↑ myocardial contractility (dp/dt) and glucose uptake in dogs with cardiomyopathy
![Page 10: Part 2 of 2. GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular](https://reader035.vdocuments.us/reader035/viewer/2022062803/56649f265503460f94c3d8ad/html5/thumbnails/10.jpg)
Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1)
Receptor Agonist Exenatide Twice Daily orOther Glucose-Lowering Therapies A retrospective analysis of the LifeLink database
JENNIE H. BEST, PHD, Diabetes Care 34:90–95, 20111
Exenatide and CV outcomes- 430,000 patients-near 40,000 on exenatide
![Page 11: Part 2 of 2. GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular](https://reader035.vdocuments.us/reader035/viewer/2022062803/56649f265503460f94c3d8ad/html5/thumbnails/11.jpg)
Insulin Secretion
β-Cell Neogenesis
β-Cell Apoptosis
Glucagon Secretion
Glucose Production
HeartHeart
GI TractLiver
MuscleDrucker DJ, Cell Metab. 2006;3:153-165.
BrainAppetite
Cardioprotection
Cardiac Output GLP-1
Stomach
Gastric Emptying
Neuroprotection
Glucose Uptake
_
+
![Page 12: Part 2 of 2. GLP-1 agonists have been shown to reduce several inflammatory markers including plasminogen activator inhibitor-1 (PAI-1), vascular](https://reader035.vdocuments.us/reader035/viewer/2022062803/56649f265503460f94c3d8ad/html5/thumbnails/12.jpg)
GLP-1 agonists not only help reduce plasma glucose levels in type-2 diabetics, but also help improve markers of cardiovascular function including blood pressure, cholesterol, and weight loss.
GLP-1 agonists are shown to have positive effects on cardiovascular outcomes and reduce the risk for heart failure
These benefits to cardiovascular health are independent of GLP-1 agonists’ effect on glucose control and add important cardiocascular effects for type-2 diabetics.